

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

14th November, 2019

Corporate Relationship Department

M/s. BSE Ltd

Dalal Street, Fort

Mumbai- 400 001

Manager - Listing

M/s. National Stock Exchange of India Ltd

"Exchange Plaza", Bandra - Kurla Complex

Bandra (E) Mumbai -400 051

Scrip Code: **524816**

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

MAnterayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.

Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/14/2019-2020

Press Release

Commercial Manufacturing Operations begin in NATCO's Visakhapatnam Formulation Facility

Hyderabad, India, November 14th, 2019

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its Finished Dosage Formulations (FDF) facility in Visakhapatnam has commenced commercial operations. The facility is a part of the Special Economic Zone (SEZ) and intended to cater primarily to the U.S. & other international markets.

Vizag facility is a key part of NATCO's capacity expansion plans for its pipeline of products and diversification into different geographies. From capability perspective, this facility will focus mostly on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment. An application with the U.S. Food and Drug Administration (USFDA) is already filed for site transfer of the first product & to trigger a regulatory audit.

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana Company Secretary &

MANEGAJano

Vice President (Legal & Corp Affairs)